The Progressive Supranuclear Palsy Clinical Trial Platform

Overview

The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.

Detailed description

The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial.

In this trial, multiple investigational products for PSP will be tested simultaneously or sequentially. Each investigational product will be tested in a regimen. Each regimen consists of a placebo-controlled trial, meaning that the active investigational product and matching placebo will be tested in each regimen.

The additional details that govern the testing of each investigational product will be summarized in separate regimen-specific appendices (RSAs). Each regimen will have a separate ClinicalTrials.gov posting, which will include specific information about the regimen. All regimen-specific outcome measures will be detailed in each regimen posting.

Participants will have an equal chance to be randomized to all regimens that are active at the time of screening. Once randomized to a regimen, participants will be randomized as outlined for each individual regimen to either study drug or placebo.

New regimens will be continuously added as new investigational products become available. PTP will enroll additional participants as each new regimen becomes available.

PTP is expected to launch with the following regimen:

* Regimen A: AADvac1 * Regimen B: LM11A-31

Interventions

• Biological AADvac1
  Active immunotherapy
• Drug LM11A-31
  Small molecule

Primary outcome measures

• Disease progression [Time frame: 52 weeks]

Secondary outcome measures (9)

• Disease progression [Time frame: 52 weeks]
• Disease progression [Time frame: 52 weeks]
• Experiences of daily living [Time frame: 52 weeks]
• Activities of daily living [Time frame: 52 weeks]
• Disease severity [Time frame: 52 weeks]
• Disease progression [Time frame: 52 weeks]
• Health-related quality of life [Time frame: 52 weeks]
• Brain volume [Time frame: 52 weeks]
• Neurodegeneration [Time frame: 52 weeks]

Eligibility criteria

Inclusion criteria

• Clinical diagnosis of possible or probable PSP Richardson's Syndrome as defined by the 2017 Movement Disorder Society (MDS) criteria.
• Presence of PSP symptoms for ≤5 years at screening (based on the best judgment of the site PI).
• Mini-Mental State Examination (MMSE) score at screening of ≥25.
• Able to walk at least 10 steps with minimal assistance (e.g., one arm for safety, but not postural support).
• Stable doses of permitted medications as described per protocol for 30 days prior to screening.
• Resides at home or in the community (assisted living is acceptable).
• As assessed by the site PI, participant is likely to be able to comply with the protocol for the duration of the study, and has adequate vision, hearing (hearing aid permitted), and literacy (English or Spanish) sufficient for compliance with the required testing procedures.

Exclusion criteria

• Females who are breastfeeding or pregnant (as documented by a urine pregnancy test) during screening, or plan to become pregnant during the study.
• Females of childbearing potential who did not use a highly effective method of contraception within 28 days of screening and/or are not willing to use a highly effective method of contraception for the duration of their participation in the study.
• Lacks good venous access such that multiple blood draws would be precluded.
• Weighs less than 40kg, or more than 136kg at screening.
• Blood transfusion within 4 weeks of screening.
• Contraindications to MRI studies, including metal (ferromagnetic) implants, a cardiac pacemaker that is not compatible with MRI, and/or severe claustrophobia.
• Screening MRI scan showing structural evidence of alternative pathology not consistent with PSP that could explain a substantial portion of the participant's symptoms as indicated by the central MRI read.
• Any unstable and/or clinically significant medical condition likely to hamper the evaluation of safety and/or efficacy of study drug (e.g., clinically significant reduction in serum B12 or folate levels, clinically significant abnormalities of thyroid function, stroke, or other cerebrovascular or cardiovascular conditions), as per the site PI's judgment.
• History of severe allergic reaction (e.g., anaphylaxis) including but not limited to: severe allergic reaction to previous vaccines, foods, and/or medications.
• Hospitalization within 30 days prior to screening or baseline.
• Infections or major surgical procedures within 3 months prior to screening, judged to be clinically significant by the site PI.
• Myocardial infarction within 1 year prior to baseline, unstable angina pectoris, symptomatic congestive heart failure.
• History of cancer within the past 5 years other than treated skin squamous cell carcinoma, basal cell carcinoma, and melanoma in-situ, localized prostate cancer not requiring treatment, or prostate or breast cancer, which have been fully removed and are considered cured.
• History or presence of immunological or inflammatory conditions, including neurological disorders, meningitis or meningoencephalitis.
• History or presence of epilepsy requiring ongoing use of antiepileptic medications. Antiepileptic medications are permitted for pain or psychiatric use per the protocol.
• DSM-5 criteria for drug or alcohol abuse or dependence currently met within the past 5 years.
• Clinically significant abnormal vital signs including sustained sitting blood pressure >160/100 mm Hg.
• Diabetes mellitus with hemoglobin A1c (HbA1c) levels of ≥8.0%.
• Known history of human immunodeficiency virus (HIV-1 or 2).
• Known history of acute/chronic hepatitis B or C unless treated curatively.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Quadruple blind

Primary purpose

Treatment

Study locations

United States · 1 center

• University of California, San Francisco — San Francisco

Identifiers

NCT: NCT07173803 · ATRI-015 · R01AG085029

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗